Pfizer's Lyrica: "Approvable" For Three Indications, But Not Generalized Anxiety
This article was originally published in The Pink Sheet Daily
Executive Summary
The company received a "non-approvable" letter for the treatment of generalized anxiety disorder. Pfizer says it is working with FDA to resolve "open issues on all indications" for the Neurontin follow-on agent.
You may also be interested in...
Lyrica Controlled Substance Scheduling Finalized By DEA
Pfizer’s pregabalin will launch in the fall for three indications as a Schedule V controlled substance.
Lyrica Controlled Substance Scheduling Finalized By DEA
Pfizer’s pregabalin will launch in the fall for three indications as a Schedule V controlled substance.
Pfizer Lyrica Undergoing Controlled Substance Scheduling At DEA
FDA clears pregabalin for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. The Neurontin follow-on compound remains "approvable" for the adjunctive treatment of partial seizures in adults with epilepsy.